The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...
Tirzepatide has been approved for treating type 2 diabetes under the trade name Mounjaro since May 2022. Zepbound is available through a prescription from a licensed medical professional for ...
The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...
As GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro gain popularity, doctors are observing a surge in patients ...
In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...
Investing in stocks with high valuations isn't necessarily a bad decision, but it's something to be done deliberately and ...
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...
The study included people taking different types drugs in this category—semaglutide (Wegovy and Ozempic), and tirzepatide (Mounjaro and Zepbound). While tirzepatide targets two hormones—GLP-1 ...
Shares of several obesity drugmakers dip after LLY lowered its revenue outlook for 2024 amid slower-than-expected sales ...
Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates. It was the second consecutive miss for the two closely watched ...